Since BRAF-mutated thyroid cancer highly correlates with the glycolytic metabolic pathway (Nagarajah et al. 2015), suppressing glycolysis may enhance the efficacy of PLX4032 in treating ATC. The gene discussed is BRAF; the disease is thyroid cancer.